Atterx Biotherapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Atterx Biotherapeutics - overview
Established
2001
Location
Madison, WI, US
Primary Industry
Biotechnology
About
Atterx Biotherapeutics, based in the US, is dedicated to developing innovative therapies aimed at combating drug-resistant bacterial infections, significantly improving treatment outcomes in healthcare settings. Atterx Biotherapeutics specializes in addressing drug-resistant bacterial infections, focusing on Catheter Associated Urinary Tract Infections (CAUTIs) and Gram-negative infections. Founded in 2001 in Madison, US, the company has executed 6 deals over its history. The current CEOs are James Millar and Steven Watt.
The company's most recent deal occurred on March 1, 2025, when Atterx raised USD 0. 59 mn in funding. Atterx Biotherapeutics specializes in developing innovative treatments aimed at preventing and treating drug-resistant bacterial infections, particularly Catheter Associated Urinary Tract Infections (CAUTIs) and Gram-negative bacterial infections. Its flagship product, C-1205, has received Fast Track Designation from the FDA.
Atterx aims to address the public health crisis of antibiotic resistance by providing effective treatment alternatives for hospitals and healthcare facilities throughout the United States. Atterx Biotherapeutics generates revenue through partnerships with healthcare providers and institutions utilizing its proprietary products for infection prevention and treatment. The company's revenue model includes direct sales to hospitals and healthcare systems, often involving contractual agreements with volume-based pricing or subscription models to enhance accessibility and ensure a steady revenue stream. Atterx Biotherapeutics is currently focused on developing new products and expanding its market presence.
The company intends to leverage its recent funding raised in March 2025 to support these initiatives, though specific new product launches and geographic expansions have not been detailed. Atterx aims to continue enhancing its treatment options for drug-resistant infections, responding to the increasing demand for effective alternatives in the healthcare market.
Current Investors
Wisconsin Investment Partners, Rosetta Partners, Michigan Rise
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Epidemiology
Website
www.atterx.com/
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.